

**TITLE**

Real-world evaluation of an intravenous iron service for the treatment of iron deficiency in patients with gastroenterological disorders

**Authors and affiliations**

Jackie Kearns;<sup>1</sup> Sudheer George Jacob<sup>1</sup>

1. Antrim Area Hospital, Northern Ireland, UK

**Corresponding author**

Jackie Kearns

Antrim Area Hospital, Northern Ireland, UK

Tel: +44 7881 654799

Email address: Jacqueline.Kearns@northerntrust.hscni.net

## SUPPLEMENTARY FILE

**Table S1: Non-IBD disorders present at baseline**

	<b>Patients with non-IBD disorders (n=66)</b>
Diagnosis, n (%)	
IDA (under investigation)	20 (30.3)
Not documented	17 (25.8)
GAVE	5 (7.6)
Coeliac disease	4 (6.1)
Menorrhagia	4 (6.1)
Barrett's oesophagus	2 (3.0)
Multiple comorbidities	2 (3.0)
Pelvic mass	2 (3.0)
Atrophic gastritis	1 (1.5)
Anaemia (under investigation)	1 (1.5)
Ascites	1 (1.5)
Cirrhosis with gastrointestinal bleeding	1 (1.5)
Cirrhosis with varices	1 (1.5)
Gynaecological	1 (1.5)
NASH with cirrhosis and haemorrhoids	1 (1.5)
Oesophageal varices	1 (1.5)
Sphincter of Oddi dysfunction	1 (1.5)
Radiation proctitis	1 (1.5)

In cases where an existing non-gastroenterological disorder may have contributed to the IDA (e.g., menorrhagia, gynaecological), or where a non-gastroenterological disorder was associated with gastroenterological complications (e.g., NASH with cirrhosis and haemorrhoids), the relevant diagnosis has been included here. It was not possible to ascertain the nature of the gastroenterological disorder for all patients as, in the treatment pathway, patients receive IV iron to treat their IDA before being referred for further investigation.

GAVE=gastric antral vascular ectasia; IDA=iron deficiency anaemia; IV=intravenous; NASH=non-alcoholic steatohepatitis

**Table S2: Baseline demographics and clinical characteristics for patients with non-IBD disorders**

<b>Demographics</b>	
Number of patients	66
Weight, kg	
Mean (SD)	66.4 (15.5)
Gender, n (%)	
Female	59 (89.4)
Male	7 (10.6)
Previously prescribed oral iron, n (%)	
Intolerant of oral iron, n (%)	8 (40.0)
Unresponsive to oral iron, n (%)	1 (5.0)
No data for response to oral iron, n (%)	11 (55.0)
<b>Clinical characteristics</b>	
Hb, g/L (n)	
Mean (SD)	(64) 100.7 (18.3)
Ferritin, µg/L (n)	
Mean (SD)	(44) 22.8 (35.1)
Median (range)	9.5 (2–160)

Hb=haemoglobin; SD=standard deviation